Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.
Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.
Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.
SGB-017 has a similar chemical structure and has also been evaluated for its potential use as an anticonvulsant.